pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,919 stories · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1021Endpoints770BioPharma Dive293BioSpace213Fierce Biotech199onclive165raps74globenewswire health73fda recalls
therapy area
allOncology5954Rare Disease1405Cardiology1088Hematology1011Immunology992Pulmonology892Vaccines885Psychiatry & CNS710
  • Exclusive: UC Berkeley startup bets on jumping genes for GLP-1 gene therapy
    The new generation of weight loss medicines does an unprecedented job of keeping off the pounds — if people stay on the drugs. Yet numerous studies suggest most of those who start taking GLP-1 drug…
    Endpoints · 3mo ago↗ source
  • International childhood vaccine campaign grows
    In today's Morning Rounds newsletter, a new era in GOP drug policy, an international childhood vaccine campaign grows, and more.
    STAT · 3mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a Trump deal with Regeneron, reclassifying medical marijuana, and more
    President Trump heralded a drug-pricing agreement with Regeneron, closing the last of 17 deals sought by the White House
    STAT · 3mo ago
← prev
page 116 of 117
next →
47
fda medwatch36
fda press28
Ophthalmology419
Endocrinology & Metabolism377
Pain371
Infectious Disease346
↗ source
  • STAT+: Sanofi MS drug gets positive review in Europe following FDA
    A multiple sclerosis drug from Sanofi that was rejected late last year by the FDA found a warmer reception in Europe.
    STAT · 3mo ago↗ source
  • Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejection
    Sanofi’s tolebrutinib is on track to get an approval in Europe for a type of multiple sclerosis even after receiving a complete response letter from the FDA in December. On Friday, the European Med…
    Endpoints · 3mo ago↗ source
  • Pfizer’s strategy chief Andrew Baum steps down; Helus Pharma swaps out CEO after two months
    → Ex-Citi analyst Andrew Baum has left his role as chief strategy and innovation officer at Pfizer, but he will be a senior strategic advisor to CEO Albert Bourla. BMO Capital Markets broke the new…
    Endpoints · 3mo ago↗ source
  • Daiichi Sankyo postpones annual results, stock dips
    Daiichi Sankyo has pushed back the reporting of its annual results, saying it needs more time to finalize the numbers. The Japanese company had intended to unveil its financials for its fiscal year…
    Endpoints · 3mo ago↗ source
  • Opinion: I started medical school at 69 and will begin residency at 72. Here’s what I learned
    Starting residency at 72 isn’t for the faint of heart. But that’s what Dawn Zuidegeest-Craft is doing.
    STAT · 3mo ago↗ source
  • Psychedelics get a boost from the White House
    In this week’s STATus Report, host Alex Hogan chats with STAT Washington correspondent Daniel Payne about Trump's psychedelics EO.
    STAT · 3mo ago↗ source
  • Opinion: The local news crisis is also a public health crisis
    Health and science reporting is often treated as optional coverage. It is anything but.
    STAT · 3mo ago↗ source
  • Growing use of guest editors has turned some journals into a ‘playground of bad science’
    The problematic use of guest editors was spotlighted last week when a genetics journal retracted nearly an entire special issue.
    STAT · 3mo ago↗ source
  • A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts
    This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts. Listen now.
    STAT · 3mo ago↗ source
  • STAT+: Trump celebrates closing first round of drug pricing deals, promises more ahead
    A deal with Regeneron was the last of 17 initially sought by the White House.
    STAT · 3mo ago↗ source
  • FDA approves Regeneron’s hearing loss gene therapy
    Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s “national priority” voucher program and will be offered to eligible patients…
    BioPharma Dive · 3mo ago↗ source
  • FDA approves Regeneron's hearing loss gene therapy Otarmeni
    Regeneron has won the first-ever FDA approval for a gene therapy to treat a rare type of inherited hearing loss, and the company plans to offer the treatment for free in the US, though that ...
    Endpoints · 3mo ago↗ source
  • Substance use disorder biotech Tempero to close after earlier 'serious' safety event
    Tempero Bio, a drug developer that had big ambitions to shake up the treatment of substance use disorders, is winding down operations, Endpoints News has learned. The shutdown comes after a "seriou…
    Endpoints · 3mo ago↗ source
  • Heart’s beat may help it beat cancer, mouse research suggests
    The constant pressure that the heart is under from beating thousands of times a day may create an environment hostile to cancers
    STAT · 3mo ago↗ source
  • STAT+: Trump’s boosting of psychedelics, cannabis signal a new era in GOP drug policy
    The Trump administration, in a stark departure from the "Just Say No" era, is funding psychedelics research and rescheduling marijuana.
    STAT · 3mo ago↗ source
  • Post-Hoc Live: MAHA, the new Trump CDC pick and RFK's vaccine agenda
    MAHA’s sway over HHS could face a fresh test now that President Trump has a new pick for CDC director: Erica Schwartz, a former deputy surgeon general. The position has been empty ...
    Endpoints · 3mo ago↗ source
  • Novartis' radioligand therapy Lutathera could soon face generic competition
    The radioligand field is on the cusp of a major competitive moment, as a rival looks to bring the first generic to a market that’s been dominated by Novartis. Radioligand therapy aims to bring the ...
    Endpoints · 3mo ago↗ source
  • Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus
    The 185-acre site will be the company’s largest single investment to date, with a focus on small-volume parenteral products like vials and prefilled syringes.
    BioPharma Dive · 3mo ago↗ source
  • STAT+: Legislatures in Colorado and Virginia resist moves to constrain drug affordability boards
    Legislators in two states are resisting efforts to restrict prescription drug affordability boards.
    STAT · 3mo ago↗ source
  • Opinion: Dropping the flu vaccine requirement puts U.S. military readiness at risk
    Since the 1918 pandemic, the military has acknowledged the threat of influenza. Now that’s changing.
    STAT · 3mo ago↗ source
  • STAT+: Sanofi research priorities in flux as new CEO logs in
    A gene therapy for deafness, all eyes on Erasca, and other biotech news from The Readout
    STAT · 3mo ago↗ source
  • Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs
    On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.
    BioPharma Dive · 3mo ago↗ source